EVALUATION OF RDW, MPV, PLATELET LABORATORY PARAMETERS IN PROSTATE CANCER PATIENTS ADMITTING TO EMERGENCY DEPARTMENT WITH HEMATURIA

Abstract

Abstract:Prostate Cancer (PCA) is the most common among urological malignant tumors. Prostate cancer patients may be unable to urinate, and may have hospital admissions with symptoms like erectile dysfunction or hematuria. Although hematuria is a highly common clinical manifestation in the society, the frequency of it is not known in prostate cancer patients, which is one of the urological malignancies. The purpose of this study was to investigate the relation of RDW (distribution width of the red blood cells), MPV (mean platelet volüme) and Platelet Blood Parameters with hematuria in prostate cancer patients admitting to the emergency clinic with hematuria. The present study was conducted retrospectively by examining the hospital automation system and patient files of prostate cancer patients admitting with hematuria between 01.01.2018-01.01.2020 to Yozgat Bozok University Emergency Medical Clinic. A total of 60 patients with full files and that matched study criteria were included in the study. For the purpose of comparing blood parameters for the purpose of comparing blood parameters, 45 patients with prostate cancer, nonspecific complaints and non-additional diseases were evaluated as the control group. MPV (mean platelet volume), RDW-CV (red blood cells distribution width) blood parameters of patients with prostate cancer hematuria were found to be significantly higher in the control group. Platelet value of the patient group was found to be significantly lower than the control group. However, the platelet blood parameter values were significantly lower in patients with major hematuria than in patients with minor hematuria (<0.05). According to the results of the present study, we believe that all the three parameters (RDW, MPV and Platelet levels), which can be measured in full blood count in the prostate cancer patient group in particular, can guide clinicians that the finding of hematuria can develop, and will be beneficial in follow-up and treatment. However, unlike RDW and MPV laboratory parameters, we think the Platelet parameter is an important parameter in predicting the type of hematuria that can develop.

Keywords

• prostate Cancer
• Hematuria
• RDW
• MPV

References

1. [1]Thomas Gillispie Smith MC III. Urologic surgery In: Townsend C, Beauchamp RD, Evers BM, et al. (eds) “Sabiston textbook of surgery: the biological basis of modern surgical practice.” 20th ed. New York: Elsevier, 2100–2102, 2017.
2. [2] Narayan VM, Konety BR and Warlick C. “Novel biomarkers for prostate cancer: an evidence-based review for use in clinical practice” Int J Urol ,24(5), 352–360, 2017.
3. [3] Siegel RL,Miller KD, Jemal A.” Cancer Istatistics” A Cancer J Clin, 65:5-29,2015.
4. [4] Nice. “Suspected cancer: recognition and referral” 1–95,2015.
5. [5] Hsieh YP, Chang CC, Kor CT, Yang Y, Wen YK, Chiu PF “The Predictive Role of Red Cell Distribution Width in Mortality among Chronic Kidney Disease Patients” PLoS One.,11(12):e0162025, 2016.
6. [6] Khadra MH, Pickard RS, Charlton M, et al. “A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice” J Urol, 163(2): 524–527,2000.
7. [7.] Mariani AJ, Mariani MC, Macchioni C “The significance of adult hematuria: 1,000 hematuria evaluations including a riskbenefit and cost-effectiveness analysis” J Urol. 141: 350–355,1989.
8. [8] Sun Y, Zhang Y, Zhu Y, Zhang A, Huang S, Yin X, Ding G, Liu M, Jia Z.”Inhibition of mitochondrial complex-1 restores the downregulation of aquaporins in obstructive nephropathy” Am J Physiol Renal Physiol. 1; 311(4),777-786,2016.

9. [9.] Gofrit ON, Katz R, Amos Shapiro A, Yutkin V, Galina Pizov G, Zorn KC, Duvdevani M, Landau EH, Pode D. “Gross Hematuria in Patients with Prostate Cancer: Etiology and Management” ISRN Surgery, 1-4,2013.
10. [10.] Hageman N, Aronsen T, Tiselius HG. “A simple device (Hemostick) fort he standardized description of macroscopic hematuria: our initial experience” Scand J Urol Nephrol,40: 149,2006.
11. [11.] Glenn S.Gerber MD, Charles B Brendler MD. “Evaluation of the urologic patient: History, physical examination, and urinalysis. Campbell-Walsh Urology” Ninth Edition. Philadelphia, 81-110,2007.
12. [12.] Gan JH, Harris AC, Green JSA. “Quantifying the risk of malignancy in patients with visible haematuria presenting to the emergency department” J Clin Urol. 8(2):132–138,2015.
13. [13.] Grossfeld GD, Litwin MS, Wolf JS, et al. “Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy–part I: definition, detection, prevalence, and etiology” Urology,57(4): 599–603,2001.
14. [14] Greenberg EM, Kaled ES. “Thrombocytopenia” Crit Care Nurs Clin North Am. 25(4):427–434,2013.
15. [15] Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM.”The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review “Chest, 139(2):271-278,2011.
16. [16] Bailey SE, Ukoumunne OC, Shephard E, Hamilton W. “How useful is thrombocytosis in predicting an underlying cancer in primary care? a systematic review” Family practice, 2016.
17. [17] Li JY, Li Y, Jiang Z, Wang RT, Wang XS. “Elevated mean platelet volume is associated with presence of colon cancer” Asian Pac J Cancer Prev, 15:10501–10504,2014.
18. [18] Elsayed AM, Mohamed GA. “Mean platelet volume and mean platelet volume/platelet count ratio as a risk stratification tool in the assessment of severity of acute ischemic stroke” Alexandria J Med. 53:67–70.2017.
19. [19] Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ, et al. “Mean platelet volume/platelet count ratio in hepatocellular carcinoma” Platelets, 24:375–377,2013.
20. [20] Omar M, Tanriverdi O, Cokmert S, Oktay E, Yersal O, Pilancı KN, et al.” Role of increased mean platelet volume (MPV) and decreased MPV/platelet count ratio as poor prognostic factors in lung cancer” Clin Respir J, 12:922–929,2018.
21. [21] Fatemi O, Torguson R, Chen F, Ahmad S, Badr S, Satler LF, Pichard AD, Kleiman NS, Waksman R. “Red cell distribution width as a bleeding predictor after percutaneous coronary intervention” Am Heart J,166(1):104-9,2013.
22. [22] Paulus EM, Weinberg JA, Magnotti LJ, Sharpe JP, Schroeppel TJ, Fabian TC, Croce MA.”Admission red cell distribution width: a novel predictor of massive transfusion after injury” Am Surg,80(7):685-9,2014.
23. [23] Lu YA, Fan PC, Lee CC, Wu VCC, Tian YC, Yang CW, Chen YC, Chang CH. “Red cell distribution width associated with adverse cardiovascular outcomes in patients with chronic kidney disease” BMC Nephrol,18: 361,2017.
24. [24] Fukuta H, Ohte N, Mukai S, Saeki T, Asada K, Wakami K, et al.” Elevated Plasma Levels of B-Type Natriuretic Peptide but not C-Reactive Protein are Associated with Higher Red Cell Distribution Width in Patients with Coronary Artery Disease” Int Heart J,50: 301-312, 2009.
25. [25] Vaya A, Hernandez JL, Zorio E, et al.” Association between red blood cell distribution width and the risk of future cardiovascular events” Clin Hemorheol Micro ,50 : 221 – 225,2012.
26. [26] Patel KV, Semba RD, Ferucci L, Newman AB, Wallece RB, Bandinelli S, et al. “Red Cell Distrubition Width and Mortality in Older Adults: A-Meta Analysis” J Gerontol A Biol Sci Med Sci ,65: 258-265,2010.
27. 27.] Öztürk ZA, Ünal A, Yiğiter R, Yesil Y, Kuyumcu ME, Neyal M, Kepekçi Y.” Is increased red cell distribution width (RDW) indicating the inflammation in Alzheimer's disease (AD)?” Arch Gerontol Geriatr,56(1):50-4,2013.
28. 28.] Albayrak S, Zengin K, Tanik S, Bakirtas H, Imamoglu A, Gurdal M. “Red cell distribution width as a predictor of prostate cancer progression” Asian Pac J Cancer Prev, 15(18):7781-4,2014.
29. 29.] Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. “A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocoldriven haematuria clinic” BJU Int,97: 301-5,2006.
30. 30] Siegel RL, Miller KD, Jemal A. “Cancer statistics” CA Cancer J Clin ,68(1):7-30,2018.
31. 31] Davis R, Jones JS, Barocas DA, et al. “Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline” J Urol, 188:2473–2481,2012.
32. [32 ] Huang XZ, Chen WJ, Zhang X, Wu CC, Zhang CY, Sun SS, Wu J. “An Elevated Platelet-to- ymphocyte Ratio Predicts Poor Prognosis and Clinicopathological Characteristics in Patients with Colorectal Cancer: A Meta-Analysis” Dis Markers 2017:1053125.
33. [33] Wang W, Bian C, Xia D, He JX, Hai P, Zhao R, Wang YY. “Combining Carcinoembryonic Antigen and Platelet to Lymphocyte Ratio to Predict Brain Metastasis of Resected Lung Adenocarcinoma Patients” Biomed Res Int ,8076384,2017.
34. [34] Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J et al.”Paraneoplastic thrombocytosis in ovarian cancer” N Engl J Med, 16; 366(7):610-8,2012. [35] Levın J, Conley Cl. “Thrombocytosıs Assocıated Wıth Malıgnant Dısease” Arch Intern Med,114():497-500,1964.
35. [36] Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J. “Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer” World J Surg,36(1):192-200,2012.
36. [37] Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R. “Impact of pretreatment thrombocytosis on survival in primary breast cancer., Austrian Breast and Colorectal Cancer Study Group” Thromb Haemost,89(6):1098-106.2003.
37. [38] Temur M, Cift T, Aktas FN.”Comparison of Hemogram and Hormone Parameters in Women with Dysfunctional Uterine Bleeding” Med J SDU / SDÜ Tıp Fak Derg ,25(1):26-32,2018.
38. [39] Toxqui L, Pérez-Granados AM, Blanco-Rojo R, Wright I, Vaquero, MP. “A simple and feasible questionnaire to estimate manstrual blood loss: relationship with hematological and gynecological parameters in young women” BMC Womens health, 30,14:71,2014.
39. [40] Işık B, Büyükcam F , Ekiz F , Atik D , Karakılıç ME.”Comparison of some of the scoring systems and mean platelet volume in the prediction of mortality in patients admitted to the emergency department with upper gastrointestinal bleeding” Abant Med J , 3(3):242-247,2014.
40. [41] Von Drygalski A, Curtis BR, Bougie DW et al.”Vancomycin-induced immune thrombocytopenia” N Engl J Med ,356:904–10, 2007.
41. [42] Piel‐Julian ML, Mahévas J. Germain L. Languille T. Comont M. Lapeyre‐Mestre “Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults” J Thromb Haemost, 16(9):1830-1842,2018.
42. [43] Bath PM, Butterworth RJ .”Platelet size: measurement, physiology and vascular disease” Blood Coagul Fibrinolysis, 7(2):157-61,1996.
43. [44] Okur N, Buyuktiryaki M, Uras N, Oncel MY, Ertekin O, Canpolat FE, Oguz SS. “Platelet mass index in very preterm infants: can it be used as a parameter for neonatal morbidities?” J Matern Fetal Neonatal Med,29:3218-3222,2016.
44. [45] Korkmaz L, Baştuğ O, Ozdemir A, Korkut S, Karaca C, Akin MA, Gunes T, Kurtoglu S, Ozturk MA. “The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index” Curr Eye Res,42:88-97,2017.
45. [46] Demiray O, Cevik E, Cuce F. “Association Between Complete Blood Count Parameters and Urinary Stone Disease” Iran Red Crescent Med J,18(7): e24319,2016.
46. [47]Senel T, Ates I,Demir BF,Arıkan MF,Karaahmetoglu S, Altiparmak E, Yilmaz N.”The diagnostic and prognostic value of platelet indices in gastrointestinal bleeding” Am J Emerg Med, 37(4):657-663,2019.
47. [48] Lowe GC, Fickowska R, Ghaithi RA, Maclachlan A, Harrison P , Lester W et al. “Investigation of the contribution of an underlying platelet defect in women with unexplained heavy menstrual bleeding” Platelets,30(1): 56–65,2019.
48. [49] Riedl J, Posch F, Königsbrügge O, Lötsch F, Reitter EM, Eigenbauer E et al. “Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality” PLoS One,9(10): e111440,2014.
49. [50] Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. “Red cell distribution width for assessment of activity of inflammatory bowel disease” Dig Dis Sci,54:842‐847,2009.
50. [51] Patel KV, Semba RD, Ferrucci L, et al. “Red cell distribution width and mortality in older adults: a meta‐analysis” J Gerontol A Biol Sci Med Sci, 65:258‐265,2010.
51. [52] Perlstein TS, Weuve J, Pfeffer MA, Beckman JA. “Red Blood Cell Distrubition Width and Mortality Risk in A Communıty-Based Prospective Cohort: NHANES III: RDW and mortality risk” Arch Intern Med,169: 588-594,2009.